

1992

**AIN-SHAMS UNIVERSITY  
FACULTY OF MEDICINE**



Lecturer of Clinical Pathology  
Faculty of Medicine  
Ain-Shams University

**DR. SALWA SAAD MOSTAPHA**

Prof. of Clinical Pathology  
Faculty of Medicine  
Ain-Shams University

**PROF. DR. ZEINAB MOHAMED TAWFIK**

Supervised By

**SUZAN HANEM MOHAMED AHMED WARRAD**

BY


Master Degree in Clinical Pathology

Submitted in Partial Fulfillment of the

**ESSAY**

**ANTIPHOSPHOLIPID ANTIBODIES  
IN VARIOUS DISEASE STATES**

45485  
201/21



S. H  
616. 919

Handwritten signatures and notes in a box.



بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ  
الْحَمْدُ لِلَّهِ الَّذِي  
خَلَقَ الْمَوَدَّعَةَ





-----  
ACKNOWLEDGEMENT

I am deeply indebted to Prof. Dr. Zainab Mohamed Tawfik ,  
Clinical pathology department for her supervision , valuable  
advice and continuous support throughout the whole work.

My deepest thanks and gratitude to Dr . Salwa Saad  
Mostafa, lecturer of clinical pathology , for her supervision  
encouragement and continuous support in this work .

My deepest thanks for my colleagues for their continuous  
encouragement and support .

Finally, no words can express my feelings to my husband,  
for his understanding and patience .

1-List of abbreviation .....	3
2-Introduction and aim of the work .....	5
3-Historical background of antiphospholipid antibodies.....	6
4-Chemistry and physical properties of phospholipids .....	9
5-The immunology of phospholipid antigen .....	15
6-The immunology of antiphospholipid antibodies.....	30
7-Affinity purification of antiphospholipid antibodies .....	36
8-Laboratory identification of antiphospholipid antibodies.....	41
9-Normal level and variations of antiphospholipid antibodies.....	52
10-Complications of antiphospholipid antibodies .....	67
11-Summary .....	81
12-References .....	84
13-Arabic Summary.....	105

-----  
CONTENTS


LIST OF ERRATA

<u>Page</u>	<u>Line</u>	<u>Error</u>	<u>Correction</u>
6	14	BFP-STIS	BFP-STIS
12	16	PH	PH
15	2	(A,B,C,D,E,F)	Removed
37	24	Immunoassays	Immunoassay
39	4	PH	PH
42	13	globulin	globulin
73	22	thrombosis	thrombosis
87	14	associated	associated
87	19	inhibition	inhibition
92	25	cardiolipin	cardiolipin
102	27	antimitrocho-	antimitrocho-ndrial

PC	: Phosphatidyl choline .
PAPS	: Primary antiphospholipid syndrome. inhibitor.
PAI-1	: Type 1 plasminogen activator
PA	: Phosphatidic acid .
M NaI	: Molar sodium iodide .
M NaCl	: Molar sodium chloride.
LE CELL	: Lupus erythematosus cell.
LA	: Lupus anticoagulant .
HIV	: Human immune deficiency virus.
ELISA	: Enzyme linked immunosorbent assay.
ds DNA	: double stranded DNA .
DRVVT	: dilute Russell Viper Venom time .
PKCT	: delta kaolin clotting time .
CNS	: Central nervous system .
CL	: Cardiolipin .
CHOL	: Cholesterol .
Ca ++	: Calcium .
	ical test of syphilis .
RFP-STIS	: Biological false positive serolog-
APTT	: Activated partial thromboplastin.
APL antibody	: Antiphospholipid antibody .
AMA	: Antimitochondrial antibody .
ACL antibody	: Anticardiolipin antibody .

-----  
LIST OF ABBREVIATION

PR	: phosphatidyl ethanolamine .
PG	: phosphatidyl glycerol.
PI	: phosphatidyl inositol.
PS	: phosphatidyl serine .
PT	: prothrombin time .
RA	: rheumatoid arthritis .
SLE	: systemic lupus erythematosus.
SM	: sphingomyelins .
T4	: T helper lymphocyte.
T8	: T suppressor lymphocyte .
T-PA	: Tissue type plasminogen activator.
TLLI	: Tissue thromboplastin inhibition
	test.
VDRL	: Venereal disease research laboratory
	antigen.




INTRODUCTION AND AIM OF THE WORK

our study aims to find in which circumstances should these antibodies be sought and which laboratory test is the best to detect them .

In addition , there have been reports of the possible association of antiphospholipid antibodies with heart valve lesions , hemolytic anemia , and neurological events such as cerebrovascular accidents and chorea , patients with these clinical and serological features have been defined as having the antiphospholipid syndrome .

Antiphospholipid antibodies are a group of auto-antibodies , mainly IgG and IgM class , directed predominantly , against negatively charged phospholipids . Several recent studies have found that patients with these antibodies are prone to repeated episodes of venous and arterial thrombosis , recurrent fetal loss , and thrombocytopenia .

-----  
INTRODUCTION AND AIM OF THE WORK



REVIEW OF LITERATURE

In 1941, Pangborn demonstrated that the active antigenic component was a phospholipid, which she termed cardiolipin (CL), and subsequently all tests had in common the principle of detection of antibodies to extracted CL (Harris, 1990).

In 1938, a program of premarital and antepartum mass blood screening for syphilis was instituted in the United States and extended to military personnel during World War II. As a result, it became clear that there were a large number of people with positive tests for syphilis without clinical or epidemiological evidence of the disease. This phenomenon was referred to as the biological false positive serological test for syphilis (BFP-ST). This was noted in two situations first, reagin was detected in the serum of patients during or after a number of infections with no syphilis, disappeared following recovery from the infection and was known as the acute BFP-ST. The second type, known as the chronic BFP-ST, there was absence of precipitating factors and it persisted over many months or years (McNeil et al., 1991).

The study of antiphospholipid (APL) antibodies began in 1907 when Wasserman introduced a diagnostic test for syphilis using a saline extract of liver from fetuses with congenital syphilis as the antigen to detect an antibody reagin in the sera of patients with syphilis (McNeil et al., 1991).

-----  
HISTORICAL BACKGROUND OF ANTIPHOSPHOLIPID ANTIBODIES

The association between LA and BFP-STs was increasingly recognized, but of interest is the fact that the LA is not found in patients with syphilis (Johansson and Lassus, 1974). Numerous studies on the mechanism of action

(Kapaport, 1972).

The term lupus anticoagulant (LA) was firstly introduced in 1972 by Reinstejn and Kapaport, who also found that this LA prolonged the whole blood clotting time and occasionally the prothrombin time, but no specific deficiency of any clotting factors was detectable (Reinstejn and

(Vermylen, 1986).

In 1952, Conley and Hartmann described a unique coagulation inhibitor in two patients with SLE who had BFP-STs reactions, whose plasma demonstrated prolongation of in vitro coagulation and also demonstrated a prolongation of the whole blood clotting time. In 1955, Rick described a similar inhibitor in an individual who did not have SLE, but also had a BFP-STs. This was the first demonstration that this inhibitor can occur independently of SLE

During the 1950s, Moor and his colleagues studied a cohort of chronic BFP-STs reactors and noted a high incidence of autoimmune diseases. Systemic lupus erythematosus (SLE) was found particularly or developed in the ensuing years of observation (McNeil et al., 1991).

The LA, is not specific for SLE as it has been described in healthy individuals, other autoimmune diseases, and in association with certain drugs, infections and malignancies ( Derksen and Kater, 1985 ).

in patients with LA compared to those without. a high incidence of BPP-STs, thrombosis, and thrombocytopenia confirmed in Lechner's review (Lechner, 1974), who also noted relation with LA alone (Feinstein and Kapaport, 1972). This was deficiency or thrombocytopenia, and occurs rarely in association with LA. It is almost always due to prothrombin phenomenon (Vermylen, 1986). Later on, it was observed that eight patients with LA who had suffered thromboembolic as early as 1963, Bowie and co-workers found four out of

haemorrhagic complications even during surgery. clear that most patients possessing LA do not suffer LA and its inhibitory effect on in vitro clotting, it became fractionated LA positive plasma and found the nature of the Lechner (1974) and Shapiro and Thiagarajan (1982)

prothrombin activator complex (Shapiro and Thiagarajan, 1982). globulin directed against the phospholipid portion of the prothrombin. Also there was evidence that LA is an immunointeraction of performed prothrombin activator complex with Lechner in 1974, they agreed that LA interferes with of LA were performed by Breckenridge et al. in 1963 and by

phospholipids are lipids containing, in addition to fatty acid and an alcohol, a phosphoric acid residue. They are composed of a glycerol backbone with a phosphodiester group at C3 linked to a polar head group alcohol, and two esterified fatty acid chains at C1, and C2 (Harper et al., 1977) .

Naturally occurring phospholipids contain saturated fatty acids at C1 locus, but those at C2 position are usually unsaturated (Merrill and Nichols, 1985) .

Phospholipids derive their names from the head group alcohol . In human cells, these head groups consist of either a nitrogenous base choline, ethanolamine, serine, glycerol, inositol or sphingosine . The resulting phospho-

lipids are :

- 1- phosphatidic acid and phosphatidyl glycerol ,
- 2- phosphatidyl choline,
- 3- phosphatidyl ethanolamine,
- 4- phosphatidyl inositol,
- 5- phosphatidyl serine,
- 6- lysophospholipids,
- 7- Plasmogens and
- 8- Sphingomyelins . (Harper et al., 1977) .